Literature DB >> 8431926

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

B Lund1, P E Kristjansen, H H Hansen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8431926     DOI： 10.1016/0305-7372(93)90026-n

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  22 in total

1.  Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.

Authors:  C F Pollera; A Ceribelli; M Crecco; C Oliva; F Calabresi
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 3.  Gemcitabine in non-small cell lung cancer (NSCLC).

Authors:  C Manegold; P Zatloukal; K Krejcy; J Blatter
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 4.  Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma.

Authors:  Robert de W Marsh; Thomas George
Journal:  Curr Gastroenterol Rep       Date:  2006-04

5.  A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study.

Authors:  Jong-Sung Park; Chang-Min Lee; Shin-Ae Lee; Chang-Kil Jung; Sung-Hyun Kim; Hyuk-Chan Kwon; Jae-Seok Kim; Hyo-Jin Kim
Journal:  Cancer Res Treat       Date:  2004-02-29       Impact factor: 4.679

Review 6.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

7.  Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study.

Authors:  Alessandra Fabi; Alessandra Mirri; Alessandra Felici; Antonello Vidiri; Andrea Pace; Emanuele Occhipinti; Francesco Cognetti; Giorgio Arcangeli; Bruno Iandolo; Maria Antonia Carosi; Giulio Metro; Carmine Maria Carapella
Journal:  J Neurooncol       Date:  2007-11-07       Impact factor: 4.130

8.  In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.

Authors:  G Metro; Z Zheng; A Fabi; M Schell; B Antoniani; M Mottolese; A N Monteiro; P Vici; S Lara Rivera; D Boulware; F Cognetti; G Bepler
Journal:  Cancer Invest       Date:  2010-02       Impact factor: 2.176

9.  Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.

Authors:  Ugur Coskun; Ali Osman Kaya; Süleyman Buyukberber; Mustafa Benekli; Aytug Uner; Mustafa Dikilitas; Banu Ozturk; Ramazan Yildiz; Secil Ozkan; Emel Yaman; Deniz Yamac
Journal:  Med Oncol       Date:  2007-09-14       Impact factor: 3.064

10.  Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.

Authors:  Athanasios Xanthopoulos; Torsten T Bauer; Torsten G Blum; Jens Kollmeier; Nicolas Schönfeld; Monika Serke
Journal:  J Occup Med Toxicol       Date:  2008-12-18       Impact factor: 2.646
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.